Recent Finacing
Recent Raise
StemSight develops off-the-shelf iPS cell–derived corneal cell therapies combined with biomaterials to treat limbal stem cell deficiency and other ocular diseases, using scalable donor-independent manufacturing.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at StemSight.
